Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.
Expert Opin Investig Drugs
; 33(8): 839-849, 2024 Aug.
Article
in En
| MEDLINE
| ID: mdl-39039690
ABSTRACT
INTRODUCTION:
Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the first for primary liver tumors. In recent years greater therapeutic advancement was represented by employment of tyrosine kinase inhibitors (TKIs) either in monotherapy or in combination with immune checkpoint inhibitors (ICIs). AREAS COVERED Major attention was given to target therapies in the last couple of years, especially in those currently under phase II trials. Priority was given either to combinations of novel ICI and TKIs or those targeting alternative mutations of major carcinogenic pathways. EXPERT OPINION As TKIs are playing a more crucial role in HCC therapeutic strategies, it is fundamental to further expand molecular testing and monitoring of acquired resistances. Despite the recent advancement in both laboratory and clinical studies, further research is necessary to face the discrepancy in clinical practice.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Carcinoma, Hepatocellular
/
Protein Kinase Inhibitors
/
Molecular Targeted Therapy
/
Drug Development
/
Immune Checkpoint Inhibitors
/
Liver Neoplasms
/
Antineoplastic Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Expert Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2024
Document type:
Article
Affiliation country:
Italia
Country of publication:
Reino Unido